Nuformix PLC Directorate Change (8880F)
21 July 2021 - 4:00PM
UK Regulatory
TIDMNFX
RNS Number : 8880F
Nuformix PLC
21 July 2021
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014. Upon the publication of this
announcement, this inside information is now considered to be in
the public domain.
Nuformix plc
("Nuformix" or the "Company")
Directorate change
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, announces that Dr Anne Brindley has decided to step
down as CEO. Anne will continue in her current position for the
next six months and has committed to assist the Company with an
orderly transition for that period.
Alastair Riddell, Non-Executive Chairman of Nuformix, said:
"Anne has been made an exceptional offer by another company which
she wants to pursue. She is committed to ensuring the progress of
the three assets in the Nuformix portfolio over the next six months
and will continue to lead this process. In particular, managing the
further preclinical work on NXP002 to deliver a more robust data
package, the further research on NXP004 and concluding the
licensing discussions on NXP001.
"We will be very sorry to see Anne go but we wish her all the
very best in her future pursuits. We look forward to providing
further updates to shareholders on the development of the portfolio
of assets in the coming months."
Enquiries:
Nuformix plc via Walbrook
Dr Alastair Riddell, Non-Executive
Chairman
Dr Anne Brindley, CEO
Allenby Capital Limited +44 (0) 20 3328 5656
Nick Athanas / George Payne (Corporate
Finance)
Stefano Aquilino / Matt Butlin (Sales
and Corporate Broking)
Walbrook PR nuformix@walbrookpr.com or +44 (0)20
7933 87 80
Anna Dunphy / Paul McManus / Tel: +44 (0)7876 741 001 / +44
Kiki Zaccagnini (0)7980 541 893
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase 1-ready assets with potential for significant value and
early licensing opportunities.
For more information, please visit www.nuformix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOARMMFTMTMTBFB
(END) Dow Jones Newswires
July 21, 2021 02:00 ET (06:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024